Last reviewed · How we verify
Autologous PRP
Autologous PRP is a Autologous cell therapy / Regenerative medicine Biologic drug developed by Iffat Anwar Medical Complex. It is currently in Phase 3 development for Musculoskeletal injuries and degenerative conditions (specific indications in Phase 3 trial unknown).
Autologous platelet-rich plasma (PRP) delivers concentrated growth factors and cytokines from the patient's own blood to promote tissue repair and regeneration.
Autologous PRP is a treatment that involves using a patient's own blood platelets to promote healing. It has been studied as a potential treatment for various perianal conditions, including perianal fistula, perianal Crohn disease, and anal fissure, and may promote the synthesis of hyaline-like cartilage repair tissue.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Autologous PRP |
|---|---|
| Sponsor | Iffat Anwar Medical Complex |
| Drug class | Autologous cell therapy / Regenerative medicine |
| Modality | Biologic |
| Therapeutic area | Regenerative Medicine / Orthopedics / Wound Healing |
| Phase | Phase 3 |
Mechanism of action
PRP is prepared by centrifuging the patient's whole blood to concentrate platelets, which are then activated to release bioactive molecules including platelet-derived growth factor (PDGF), vascular endothelial growth factor (VEGF), and transforming growth factor-beta (TGF-β). These factors stimulate angiogenesis, cell proliferation, and extracellular matrix deposition to accelerate healing of damaged tissues.
Approved indications
- Musculoskeletal injuries and degenerative conditions (specific indications in Phase 3 trial unknown)
Common side effects
- Injection site pain or discomfort
- Mild swelling or inflammation at injection site
- Infection risk (minimal with proper sterile technique)
Key clinical trials
- PRP Injection Into the Sacroiliac Joint After Ipsilateral THA: Effects on Early Recovery and Function (SIJ-THA Randomized Trial) (NA)
- Thumb Base Osteoarthritis: Ultrasound-guided Platelet-rich Plasma Versus Placebo Injection (PHASE2)
- Treatment of Patellofemoral Osteoarthritis With Engineered Cartilage. (PHASE2)
- Subtenon Autologous Platelet-Rich Plasma in Inherited and Degenerative Retinal Diseases (PHASE1, PHASE2)
- PANDORA: Evaluation of Platelet-rich Plasma in Non-tumoural Odour Disorders: a Descriptive Pilot Study. (NA)
- Comparison of Platelet-Rich Plasma and Prolotherapy for Plantar Fasciitis (NA)
- Extracorporeal Shockwave Therapy and Platelet-Rich Plasma for Midportion Achilles Tendinopathy (NA)
- Comparison of Platelet-rich Plasma and Activated Cytokine-rich Serum Injection Treatments in Patients With Knee Osteoarthritis. (KOA PRP ACS) (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Autologous PRP CI brief — competitive landscape report
- Autologous PRP updates RSS · CI watch RSS
- Iffat Anwar Medical Complex portfolio CI
Frequently asked questions about Autologous PRP
What is Autologous PRP?
How does Autologous PRP work?
What is Autologous PRP used for?
Who makes Autologous PRP?
What drug class is Autologous PRP in?
What development phase is Autologous PRP in?
What are the side effects of Autologous PRP?
Related
- Drug class: All Autologous cell therapy / Regenerative medicine drugs
- Manufacturer: Iffat Anwar Medical Complex — full pipeline
- Therapeutic area: All drugs in Regenerative Medicine / Orthopedics / Wound Healing
- Indication: Drugs for Musculoskeletal injuries and degenerative conditions (specific indications in Phase 3 trial unknown)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing